Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT05988177
NA

Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections

Sponsor: Beijing Friendship Hospital

View on ClinicalTrials.gov

Summary

This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.

Official title: Clinical Study on the Efficacy and Safety of Carrimycin Tablets in Hemophagocytic Lymphohistiocytosis Patients With Carbapenem-resistant Infections

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2023-08-30

Completion Date

2026-12-30

Last Updated

2023-08-14

Healthy Volunteers

No

Interventions

DRUG

Carrimycin tablets

Carrimycin tablets are administered 400mg a day orally for 7 days.

Locations (1)

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China